目的探讨G蛋白偶联受体34(G—proteincoupledreceptor34,GPR34)的表达与肝细胞癌发生发展的相关性。方法应用肝细胞癌组织芯片和免疫组织化学技术,检测GPR34蛋白在44例肝细胞癌组织中的表达,X2检验和Fisher检验及Spearman相关检验,分析GPR34表达与肝细胞癌临床病理特点的相关性,应用Kaplan—Meier方法计算肝细胞癌患者术后5年生存率及生存时间。结果GPR34在肝细胞癌组织中的表达比癌旁组织明显上调(P=0.003);GPR34表达与肝细胞癌大小(P=0.024)、小肝癌(P=0.030)和浸润深度(P=0.012)显著相关,与性别、年龄、肝硬化、组织分化程度及临床分期无明显相关性(P〉0.05);高表达和低表达GPR34的患者术后5年累积生存率分别为56.6%和66.0%,中位生存时间为59.0(95%凹:49.9~68.1)个月和65.0(95%CI:56.4~73.6)个月,Kaplan-Meier分析显示其差异有统计学意义(X2=5.617,P=0.018)。多因素分析显示,GPR34可以作为一个独立的预后评估因素(P=0.037)。结论GPR34在肝细胞癌组织中的表达上调,提示GPR34在其中具有促癌作用。GPR34表达上调与肝细胞癌大小、小肝癌、浸润深度和患者的生存时间相关。GPR34表达上调可以作为肝细胞癌预后不良评估的一个潜在影响因素。
Objective To determine the expression of G-protein coupled receptor 34 (GPR34) in hepatocellular carcinoma tissues. Methods Immunohistochemistry and tissue-array were used to determine GPR34 expression in human hepatocellular carcinoma tissues and matched adjacent tissues. A statistical analysis was performed to establish the potential correlation between GPR34 expression and the patients' clinicopathological characteristics, tumor progression, and prognosis. Results GPR34 is up-regulated in primary hepatocellular carcinoma tissues compared with matched adjacent tissues (P = 0. 003 ), and it was shown that GPR34 expression is significantly correlated with tumor size ( P = 0. 024), small hepatocellular carcinoma(0.030) and infiltration(P =0.012), but not with sex, age, grade, clinical stage (all P 〉 0. 05 ) ; it was also shown that GPR34 expression had a significant influence on prognosis ( X2 = 5. 617, P = 0. 018). Multivariate analyses showed that high GPR34 expression is an independent poor prognostic factor for overall survival (P = 0. 037 ). Conclusions The up-regulation of GPR34 acts as an potential pro- oncogene in the development and progression of hepatocellular carcinoma. GPR34 may be a useful diagnostic or prognostic molecular biomarker, and a potential target for therapeutic intervention.